Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) have earned a consensus recommendation of “Moderate Buy” from the twelve brokerages that are presently covering the company, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, four have given a hold recommendation and seven have issued a buy recommendation on the company. The average 12-month price objective among brokerages that have issued ratings on the stock in the last year is $36.00.

Several brokerages have weighed in on ARCT. Wall Street Zen downgraded Arcturus Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday. Guggenheim downgraded Arcturus Therapeutics from a “buy” rating to a “neutral” rating in a research note on Wednesday, October 22nd. Leerink Partners reduced their price target on Arcturus Therapeutics from $63.00 to $54.00 and set an “outperform” rating for the company in a research report on Friday, August 22nd. Zacks Research downgraded Arcturus Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Friday, October 24th. Finally, Piper Sandler dropped their price objective on shares of Arcturus Therapeutics from $140.00 to $72.00 and set an “overweight” rating on the stock in a research note on Tuesday, November 11th.

Arcturus Therapeutics Trading Down 1.7%

ARCT opened at $7.13 on Wednesday. Arcturus Therapeutics has a 12-month low of $5.85 and a 12-month high of $24.17. The firm has a 50 day moving average of $10.56 and a two-hundred day moving average of $13.81. The firm has a market capitalization of $202.56 million, a PE ratio of -2.90 and a beta of 2.10.

Arcturus Therapeutics (NASDAQ:ARCT) last released its quarterly earnings data on Monday, November 10th. The biotechnology company reported ($0.49) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.09) by $0.60. Arcturus Therapeutics had a negative net margin of 68.35% and a negative return on equity of 28.68%. The firm had revenue of $17.15 million for the quarter, compared to analyst estimates of $17.47 million. As a group, analysts predict that Arcturus Therapeutics will post -2.22 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Goldman Sachs Group Inc. raised its stake in shares of Arcturus Therapeutics by 9.1% during the 1st quarter. Goldman Sachs Group Inc. now owns 509,712 shares of the biotechnology company’s stock worth $5,398,000 after buying an additional 42,636 shares during the period. Dynamic Technology Lab Private Ltd purchased a new stake in Arcturus Therapeutics in the 1st quarter worth $299,000. Invesco Ltd. raised its position in Arcturus Therapeutics by 83.1% during the first quarter. Invesco Ltd. now owns 34,896 shares of the biotechnology company’s stock worth $370,000 after acquiring an additional 15,836 shares during the period. Public Employees Retirement System of Ohio purchased a new position in Arcturus Therapeutics during the second quarter valued at $240,000. Finally, Jacobs Levy Equity Management Inc. grew its position in shares of Arcturus Therapeutics by 20.6% in the first quarter. Jacobs Levy Equity Management Inc. now owns 144,141 shares of the biotechnology company’s stock valued at $1,526,000 after purchasing an additional 24,583 shares during the period. Hedge funds and other institutional investors own 94.54% of the company’s stock.

About Arcturus Therapeutics

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.